NCT02958969 · OUTCOME

Frequency of Atherothrombotic Events

Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma · Source last updated 2019-12-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: 6 months

What was measured

6-month rates of myocardial infarction and stroke will be calculated.

Groups in this outcome

Apixaban

apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months Apixaban: apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Apixaban	50

Reported measurements

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Apixaban	0	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
0

denoms

counts
group Id
OG000
value
50
units
Participants

description

6-month rates of myocardial infarction and stroke will be calculated.

groups

description
apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months Apixaban: apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months
id
OG000
title
Apixaban

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

6 months

title

Frequency of Atherothrombotic Events

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice